Nemaura Medical announces next commercialization stage of its proBEAT platform

Nemaura Medical announces the next commercialization stage of its proBEAT sensor and AI-based feedback platform, augmenting the BEATdiabetes program. The pilots are intended as a precursor to revenue generating contracts for proBEAT and will commence over the coming weeks and months. The Company is continuing its discussions with corporations and health insurers in the U.S. to further increase the number of pilots that will run in calendar year 2023. Dr. Faz Chowdhury, Nemaura’s Chief Executive Officer, stated, “The expansion of the BEATdiabetes program into employers and insurers in the U.S. represents significant progress towards bringing more innovative diabetes care solutions to our target markets. Importantly to Nemaura, this is a big step toward revenue generation with our proBEAT(TM) platform, and we aim to continue the momentum over the coming months and years. We spent a vast amount of time and resource optimizing and scaling our sensor manufacturing processes and it’s extremely fulfilling for the team to see their hard work come to fruition through these developments, bringing cost-effective solutions to the market.”